Cocrystal Pharma (STU:8CC) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cocrystal Pharma's Free Cash Flow for the three months ended in Mar. 2024 was €-4.15 Mil. Cocrystal Pharma's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Cocrystal Pharma's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Cocrystal Pharma's current FCF Yield % is -76.63%.

The historical rank and industry rank for Cocrystal Pharma's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Cocrystal Pharma was -26.02%. The lowest was -66855.56%. And the median was -7080.77%.

STU:8CC's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.92
* Ranked among companies with meaningful FCF Margin % only.

Cocrystal Pharma FCF Margin % Historical Data

The historical data trend for Cocrystal Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma FCF Margin % Chart

Cocrystal Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-26.03

-499.82

Cocrystal Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cocrystal Pharma's FCF Margin %

For the Biotechnology subindustry, Cocrystal Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's FCF Margin % falls into.

Cocrystal Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cocrystal Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.557	/	0
	=	%

Cocrystal Pharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.15	/	0
	=	%

Cocrystal Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cocrystal Pharma (STU:8CC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

COCP:USA

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma (STU:8CC) Headlines

No Headlines